

## Wellnex Life Limited (ASX:WNX)

Completion of Placement to strategic investors at \$1.40 per share

### Investment Highlights

- Wellnex Life has completed a placement to strategic investors at an 86% premium to the current share price at \$1.40 per share
- Placement validates the future plans of the business
- Wellnex Life continues to see strong brand sales with orders in December to date of circa \$1.6 million for the month.

**Wellnex Life Limited (ASX) ("Wellnex Life" or the "Company")**, is pleased to announce that it has finalised a placement of \$450,000 with strategic investors at an 86% premium to the current share price at \$1.40 per share (\$0.75 – closing price 19 December 2024). The placement at a substantial premium validates the future business plans with growing sales and the progression of the dual listing on the London Stock Exchange.

Wellnex Life continues to see growth in its brand sales with orders in December to date for the Wellnex brands at circa \$1.6 million, compared to brand sales in December 2023 of \$0.28 million. The growth in brand sales reflects the strong performance of Pain Away and Wakey Wakey with Wakey Wakey sales in the first half of FY25 above budget.

IP licensing continues to grow in sales, with first products for the UK launch with Haleon delivered coupled with increasing demand from our other customer for Wellnex's innovative range of liquid analgesics.

The Company intends to use its ASX Listing Rule 7.1 placement capacity for the issue of 321,429 shares.

This ASX announcement has been authorised by the Board of Wellnex Life Limited (ASX:WNX)

For further information, please contact:

### Wellnex Life Limited (ASX:WNX)

George Karafotias

Chief Executive Officer

P: +61 3 8399 9419

E: [george.k@wellnexlife.com.au](mailto:george.k@wellnexlife.com.au)

For personal use only

# WELLNEX

## About Wellnex Life

Wellnex Life Limited (ASX: WNX) is a consumer healthcare business with a track record for developing, licensing, and marketing registered products and brands to customers in the growing healthcare market segment. Since listing in 2021, Wellnex Life has successfully launched a host of brands and products now ranged in major retailers in the healthcare market space, pharmacies and supermarkets included. Its distribution arrangements have seen Wellnex Life secure significant licensing arrangements with major pharmaceutical companies in Australia and globally that have given the company's registered products a distribution channel with a steadily increasing global geographic footprint.

Wellnex Life has more recently acquired leading Australian topical pain relief brand Pain Away. Its addition to Wellnex Life's product offering both compliments and accelerates the potential growth of the company's business operations. This transformational acquisition gives added impetus to Wellnex Life's financial growth and scale and reinforces its place as a major and respected participant in the growing healthcare market, both in Australia and overseas.

To learn more, please visit: [www.wellnexlife.com.au/](http://www.wellnexlife.com.au/)

For personal use only